摘要
目的探讨肝癌合并乙肝伴有高HBV DNA病毒载量患者接受免疫和靶向治疗的安全性。方法针对1例肝癌合并乙肝伴有高HBV DNA病毒载量接受抗病毒和免疫治疗的病例,查阅文献,分析其治疗方案及药学监护。结果患者抗肿瘤治疗前启动抗乙肝病毒治疗,同时接受免疫和抗病毒治疗,治疗期间监护患者肝功能,未出现乙肝病毒再激活。结论肝癌合并乙肝的患者,如乙肝表面抗原和/或HBV DNA阳性,在接受免疫治疗的同时应合并使用抗病毒药物。
Objective To investigate the safety of immune and targeted therapy for patients with hepatocellular carcinoma complicated with hepatitis B and high HBV DNA viral load.Methods A case of hepatocellular carcinoma complicated with hepatitis B and high HBV DNA viral load receiving antiviral and immunotherapy was analyzed,and the treatment plan and pharmaceutical care were analyzed.Results The patient began anti-hepatitis B antiviral therapy before anti-tumor therapy,and received immune and antiviral therapy at the same time.The patient's liver function was monitored during treatment,and hepatitis B virus reactivation did not occur.Conclusion If the patients with hepatocellular carcinoma and hepatitis B are positive for hepatitis B surface antigen and/or HBV DNA,they should use antiviral drugs combined with immunotherapy.
作者
唐丽英
刘丽萍
宁洁
江洁美
Tang Liying;Liu Liping;Ning Jie;Jiang Jiemei(Department of Pharmacy,Gengjiu Clinical College of Anhui Medical University,Hefei 230051,China;Department of Oncology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China;Department of Pharmacy,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)
出处
《实用药物与临床》
2025年第3期197-200,共4页
Practical Pharmacy and Clinical Remedies
基金
安徽省卫生健康委科研项目(AHWJ2023BAa10001)。
关键词
肝癌
乙肝
HBV再激活
免疫治疗
Hepatocellular carcinoma
Hepatitis B
HBV reactivation
Immunotherapy
